Xaira Therapeutics is an innovative biotech startup dedicated to transforming drug discovery and development through the power of artificial intelligence. The company specializes in developing generative AI models aimed at designing protein and antibody therapeutics, particularly for challenging molecular targets. By creating foundational models for biology and disease, Xaira enhances target elucidation and patient stratification, ultimately facilitating the identification of novel therapies and improving drug development success rates. Headquartered in the San Francisco Bay Area, Seattle, and London, Xaira is committed to leveraging cutting-edge technology to make a significant impact on global health.